A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants

← catalyst calendar

NCT06547164

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase

Phase 1

Status

Completed

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

40actual

Sites

Country

United Kingdom

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-08-27

actual

When the study began enrolling

Primary completion

2025-08-20

actual

The date the last participant is measured for the primary outcome — the readout window

Study completion

2025-08-20

actual

The whole study's end, after follow-up

First posted

2024-08-09

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2025-09-04

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Healthy Participants

Interventions

Drug: Midazolam
Drug: Camizestrant — also filed as AZD9833
Drug: Carbamazepine

Primary outcomes

what the primary-completion date above is the date OF

Part A: Area under concentration-time curve from time 0 to infinity (AUCinf) of midazolam

measured Period 1 (Day 1) and Period 3 (Day 7 to Day 8)

Part A: Area under concentrationcurve from time 0 to the last quantifiable concentration (AUClast) of midazolam

measured Period 1 (Day 1) and Period 3 (Day 7 to Day 8)

Part A: Maximum observed plasma (peak) drug concentration (Cmax) of midazolam

measured Period 1 (Day 1) and Period 3 (Day 7 to Day 8)

Part B: Area under concentration-time curve from time 0 to infinity (AUCinf) of camizestrant

measured Period 1 (Day 1 to Day 4), Period 2 (Day 22 to Day 25)

Part B: Area under concentrationcurve from time 0 to the last quantifiable concentration (AUClast) of camizestrant

measured Period 1 (Day 1 to Day 4), Period 2 (Day 22 to Day 25)

Part B: Maximum observed plasma (peak) drug concentration (Cmax) of camizestrant

measured Period 1 (Day 1 to Day 4), Period 2 (Day 22 to Day 25)

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed